Anita Chabria is a California columnist for the Los Angeles Times, based in Sacramento. Before joining The Times, she worked for the Sacramento Bee as a member of its statewide investigative team ...

On most days, Brandeis professor Anita Hannig teaches about and researches the anthropology ... decided to use the money to scale and sleep on the side of a cliff in Canada’s Pacific Ranges. “I’ve ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Across the recent three months, 4 analysts have shared their insights on Teva Pharmaceutical Indus TEVA, expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Click the FOLLOW button to be the first to know about this artist's upcoming lots, sold lots, exhibitions and articles ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq Composite (NASDAQINDEX: ^IXIC) lost 0.5% and 0.9% ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

China is quick to act when US tariffs on its imports go into effect, but experts say it’s leaving room for negotiation. New drone video shows wreckage from midair collision near DC airport ...